Alnylam to webcast investor event to discuss results from kardia-2 phase 2 study of zilebesiran at american college of cardiology scientific session

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that it will host a webcast event to discuss results from the kardia-2 phase 2 study of zilebesiran, an investigational rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of hypertension, at the american college of cardiology (acc) scientific session on sunday, april 7, 2024 at 7:00 pm et. the event will include pr.
ALNY Ratings Summary
ALNY Quant Ranking